Teleflex Incorporated (TFX) is set to present at the 43rd J.P. Morgan Healthcare Conference. Its shares were acquired by financial giant JPMorgan Chase & Co., but also sold by Stifel Financial Corp. Legal firm Glancy Prongay & Murray LLP announced an investigation of the company. Mixed financial results are speculated to be driving negative sentiment towards the company. Vizient awarded the company with a short-term central venous catheters contract. Third quarter earnings from TFX met expectations, but the stock suffered a dip due to a lowered revenue outlook for 2024. The average price target set by analysts is $252.50. Teleflex reported growth despite operating in a difficult healthcare sector. one of its key offerings, the UroLift 2, with advanced tissue control was launched recently and its CEO, Liam Kelly, presented at the recent healthcare conference. However, earnings and shareholder returns have seen a downward trend in the past week. The company launched the next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada.
Teleflex Incorporated TFX News Analytics from Fri, 02 Dec 2016 08:00:00 GMT to Sat, 11 Jan 2025 07:16:02 GMT -
Rating -3
- Innovation 2
- Information 6
- Rumor -5
